Expert Rev Anticancer Ther. 2012;12(1):41-49. © 2012 Expert Reviews Ltd. Uterine serous cancer (USC) is a highly aggressive variant of endometrial cancer. USC is ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 31.29%, which has investors questioning if this is right time to sell.

D tumoroid models transform cancer research, accurately reflecting tumor biology and enabling effective drug testing and ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other cancers as well.

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

Dr. Scott Kamelle MILWAUKEE, WI, UNITED STATES, January 31, 2025 /EINPresswire / -- Milwaukee, WI – Dr. Scott Kamelle , a dedicated Gynecologi ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

Immunotherapeutics have transformed cancer outcomes. It is crucial that response patterns seen with them are assessed ...

4 cm in greatest dimension IVA Tumor invasion bladder and/or bowel mucosa IVB Distant metastases including abdominal metastases and/or inguinal lymph nodes Uterine sarcomas ...

Equities research analysts at Wedbush boosted their FY2024 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Wedbush analyst R.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price target lowered by HC Wainwright from $20.00 to $10.00 in a research report released on Wednesday,Benzinga reports. The firm currently ...